Filter Results :

Your search for Pharmaceuticals returned 5434 reports

Sort by


Australia Pharmaceuticals and Healthcare Report

28 Sep 2016  |  Published by:  BMI Pharmaceuticals and Healthcare
BMI View: The incumbent Liberal-National coalition's victory in Australia's federal elections will not bring about a clear policy direction for the healthcare sector. While the government has a fresh mandate to enact its policies, it is considerably weaker from the previous election and will be cons...

$ 1,295.00

Read More

Croatia Pharmaceuticals and Healthcare Report

28 Sep 2016  |  Published by:  BMI Pharmaceuticals and Healthcare
BMI View: Continued political instability coupled with a bleak economic outlook will continue to repress the pharmaceutical and healthcare sectors in Croatia. Necessary austerity measures will impose further barriers towards growth and reduce the use of high-value patented drugs, highlighting minima...

$ 1,295.00

Read More

Hungary Pharmaceuticals and Healthcare Report

28 Sep 2016  |  Published by:  BMI Pharmaceuticals and Healthcare
BMI View: The Hungarian government's fiscal stimulus initiatives will boost the private consumption of pharmaceuticals, particularly the over the counter medicines segment. A secondary set of initiatives are aimed at increasing domestic production capabilities, such as the pharmaceutical sector. Whi...

$ 1,295.00

Read More

Iran Pharmaceuticals and Healthcare Report

28 Sep 2016  |  Published by:  BMI Pharmaceuticals and Healthcare
BMI View: The removal of economic sanctions heralds an era of uncertainty for Iran's pharmaceutical market. Underlying issues regarding the operating environment will prevent an immediate uptick in multinational drugmaker interest; rather, this will be a gradual process. Nevertheless, there has been...

$ 1,295.00

Read More

Ireland Pharmaceuticals and Healthcare Report

28 Sep 2016  |  Published by:  BMI Pharmaceuticals and Healthcare
BMI View: The Irish government's four-year agreement with the pharmaceutical industry with regard to drug pricing reflects the government's continued focus on cost control measures targeting pharmaceutical expenditure. The agreed price-reduction mechanism for existing medicines will, however, allow ...

$ 1,295.00

Read More

Levulinic Acid Market by Application (Plasticizers, Pharmaceuticals & Cosmetics), Technology (Acid Hydrolysis, Biofine), and Region (North America, Europe, Asia-Pacific and Rest of the World) - Global Forecast to 2021

27 Sep 2016  |  Published by:  MarketsandMarkets
The levulinic acid market is projected to reach USD 32.5 million by 2021The levulinic acid market is projected to reach USD 32.5 million by 2021, at a CAGR of 14.0% between 2016 and 2021. Increasing consumption of levulinic acid by pharmaceuticals and cosmetics industries is one of the significant f...

$ 5,650.00

Read More

Sudan and South Sudan Pharmaceuticals and Healthcare Report

21 Sep 2016  |  Published by:  BMI Pharmaceuticals and Healthcare
BMI View: Economic and political challenges will continue to undermine growth within Sudan and South Sudan's pharmaceutical and healthcare markets. As such, political instability will remain a barrier to any significant investment in the sector, whilst disagreements about oil revenue sharing will af...

$ 1,295.00

Read More

Sweden Pharmaceuticals and Healthcare Report

21 Sep 2016  |  Published by:  BMI Pharmaceuticals and Healthcare
BMI View: Declining government reimbursement for prescription medicines and the promotion of lowervalue generic medicines does not bode well for innovative drugmakers selling their products in Sweden, particularly as the government is the primary purchaser of pharmaceuticals. Over the long term, pus...

$ 1,295.00

Read More

Switzerland Pharmaceuticals and Healthcare Report

21 Sep 2016  |  Published by:  BMI Pharmaceuticals and Healthcare
BMI View: Switzerland will remain amongst the wealthiest countries in the world in real GDP per capita terms, which together with an aging population and a preference for patented medicines, will keep pharmaceutical spending high. However, faced with growing healthcare costs, the Swiss government wi...

$ 1,295.00

Read More

Oman Pharmaceuticals and Healthcare Report

21 Sep 2016  |  Published by:  BMI Pharmaceuticals and Healthcare
BMI View: The Oman Ministry of Health's decision to postpone the latest phase of medicine price reductions highlights the opaque nature of the country's pharmaceutical sector. Over the long term, Oman's population will benefit from more affordable healthcare services as even more medicines are reduc...

$ 1,295.00

Read More

Puerto Rico Pharmaceuticals and Healthcare Report

21 Sep 2016  |  Published by:  BMI Pharmaceuticals and Healthcare
BMI View: An expected increase in US government funding to strengthen Puerto Rico's healthcare system will support pharmaceutical and healthcare sector growth in the commonwealth over the next few years. While the US administration will continue to seek legislative removal of Puerto Rico's Medicaid ...

$ 1,295.00

Read More

Serbia Pharmaceuticals and Healthcare Report

21 Sep 2016  |  Published by:  BMI Pharmaceuticals and Healthcare
BMI View: Serbia will remain an unattractive market for multinational drugmakers in comparison to its regional neighbours. Government cost-containment, via severe drug price cuts, and continued economic issues will dampen the country's growth outlook.Headline Expenditure ProjectionsPharmaceuticals: ...

$ 1,295.00

Read More

Singapore Pharmaceuticals and Healthcare Report

21 Sep 2016  |  Published by:  BMI Pharmaceuticals and Healthcare
BMI View: The delivery of healthcare in Singapore will continue to change as the country looks to deepen the integration of technology with its medical sector. This will see a shift in the flow of patients seeking medical services, their interaction with physicians and potentially the use of pharmac...

$ 1,295.00

Read More

Pakistan Pharmaceuticals and Healthcare Report

21 Sep 2016  |  Published by:  BMI Pharmaceuticals and Healthcare
BMI View: Pakistan's pharmaceutical market will remain a low priority for innovative drugmakers. Downward price pressures on pharmaceutical prices coupled with uncertainty surrounding the country's policy direction impinge on potential commercial opportunities, while a fragmented procurement system ...

$ 1,295.00

Read More

Iraq Pharmaceuticals and Healthcare Report

21 Sep 2016  |  Published by:  BMI Pharmaceuticals and Healthcare
BMI View: Iraq's ailing domestic landscape will dampen investor confidence in the country's pharmaceuticals and healthcare sectors over at least the next few years if not longer. Although the government remains committed to healthcare provision, economic and security headwinds will mean internationa...

$ 1,295.00

Read More
Total 5434 records.